SCHEMBL1777309

SCHEMBL1777309

Cc1c(F)c(O)c(C(=O)Nc2ccc(Cl)nn2)c(=O)n1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.43
MAPT P10636 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 3/20 0.43
HPGD P15428 2/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RAB9A P51151 7/20 0.40
KDM4E B2RXH2 3/20 0.40
TP53 P04637 3/20 0.40
USP2 O75604 2/20 0.40
HTT P42858 1/20 0.40
BRD4 O60885 1/20 0.37
POLB P06746 1/20 0.37
NLRP3 Q96P20 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12605339 0.88 NPC1 (0.44) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL1780290 0.88 NPC1 (0.44) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL12605345 0.86 NPC1 (0.43) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL1776499 0.85 NPC1 (0.42) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL1779685 0.84 NPC1 (0.41) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL12605350 0.83 NPC1 (0.43) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL1399907 0.80 NPC1 (0.65) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL1779089 0.79 RAB9A (0.59) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL12605343 0.78 ALDH1A1 (0.41) NPC1MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL12601082 0.75 NPC1 (0.50) NPC1MAPTSMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943614-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-7943614-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-7943614-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
EP-1902047-B1 CARBOXAMIDE COMPOUND AND USE OF THE SAME SUMITOMO CHEMICAL CO (JP) 2010-04-28 EP disclosed
US-20090111815-A1 Carboxamide Compound and Use of the Same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-30 US disclosed
US-20090111815-A1 Carboxamide Compound and Use of the Same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-30 US disclosed
US-20090111815-A1 Carboxamide Compound and Use of the Same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111815-A1 Carboxamide Compound and Use of the Same NAA50, SIRT1, NQO2 NPC1 1353/4885MAPT 2326/4885SMN1; SMN2 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.